University Hospital of Zurich, Clinic for Gynaecology
Zurich, 8091, Switzerland
NCT Number: NCT01042119
The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.
The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Zurich, 8091, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Time frame: 1 year
University of Zurich
Other
Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06170450
Overactive Bladder Syndrome
Louisville, Kentucky, United States
View Trial DetailsNCT06389838
Female Urinary Stress Incontinence, Female Urogenital Diseases
Mainz, Germany
View Trial DetailsNCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial DetailsNCT05308979
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orange, California, United States
View Trial Details